Reported Saturday, Genmab Reports Rina-S Showed 45.9% ORR, 9.5-Month mPFS And 12.1-Month mDOR In Platinum-Resistant Ovarian Cancer, With Activity Regardless Of FRα Expression Levels

Benzinga Newsdesk www.benzinga.com Positive 90.7%

Neg 0% Neu 0% Pos 90.7%

Treatment with Rina-S 120 mg/m² every three weeks demonstrated a clinically meaningful objective response rate (ORR) and durable median duration of response (mDOR) in patients with platinum-resistant ovarian cancer (PROC)
Antitumor activity was observed regardless of folate receptor alpha (FRα) expression levels, including low FRα expression and non-expressors

Comments

No comments yet. Be the first!